Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) EBITDA (2016 - 2025)

Historic EBITDA for Jaguar Health (JAGX) over the last 11 years, with Q3 2025 value amounting to -$7.2 million.

  • Jaguar Health's EBITDA rose 33.05% to -$7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.8 million, marking a year-over-year decrease of 857.4%. This contributed to the annual value of -$30.8 million for FY2024, which is 1009.01% up from last year.
  • Latest data reveals that Jaguar Health reported EBITDA of -$7.2 million as of Q3 2025, which was up 33.05% from -$8.0 million recorded in Q2 2025.
  • Jaguar Health's 5-year EBITDA high stood at -$6.3 million for Q4 2022, and its period low was -$11.8 million during Q1 2022.
  • Moreover, its 5-year median value for EBITDA was -$8.2 million (2024), whereas its average is -$8.7 million.
  • As far as peak fluctuations go, Jaguar Health's EBITDA plummeted by 10944.46% in 2021, and later skyrocketed by 4405.01% in 2022.
  • Jaguar Health's EBITDA (Quarter) stood at -$10.8 million in 2021, then skyrocketed by 41.91% to -$6.3 million in 2022, then dropped by 20.22% to -$7.6 million in 2023, then decreased by 7.94% to -$8.2 million in 2024, then grew by 11.27% to -$7.2 million in 2025.
  • Its EBITDA stands at -$7.2 million for Q3 2025, versus -$8.0 million for Q2 2025 and -$9.4 million for Q1 2025.